Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  July 2020  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
    1  2  3  4  5
  6  7  8  9101112
13141516171819
20212223242526
2728293031  

Latest IDIGH Publications

  1. Harris, M., Brouillette, M.-J., Scott, S. C., Smaill, F., Smith, G., Thomas, R., Fellows, L. K. & Mayo, N. E.
    (2020)
    .
    Impact of Loneliness on Brain Health and Quality of Life Among Adults Living With HIV in Canada
    .
    Journal of acquired immune deficiency syndromes (1999)
    ,
    vol
    .
    84
    ,
    p
    .
    336-344
    .
  2. Balram, B., Lubov, J., Theoret, Y., Afif, W., Bitton, A., Wild, G., Lakatos, P. L. & Bessissow, T.
    (2020)
    .
    Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy
    .
    Digestive diseases and sciences
  3. Lima, N. S., Takata, H., Huang, S.-H., Haregot, A., Mitchell, J., Blackmore, S., Garland, A., Sy, A., Cartwright, P., Routy, J.-P., Michael, N. L., Appay, V., Jones, R. B. & Trautmann, L.
    (2020)
    .
    CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir
    .
    Journal of immunology (Baltimore, Md. : 1950)
  4. Langedijk, A. C., Lebbink, R. J., Naaktgeboren, C., Evers, A., Viveen, M. C., Greenough, A., Heikkinen, T., Stein, R. T., Richmond, P., Martinón-Torres, F., Nunes, M., Hosoya, M., Keller, C., Bauck, M., Cohen, R., Papenburg, J., Pernica, J., Hennus, M. P., Jin, H., Tabor, D. E., Tovchigrechko, A., Ruzin, A., Abram, M. E., Wilkins, D., Wildenbeest, J. G., Kragten-Tabatabaie, L., Coenjaerts, F. E. J., Esser, M. T. & Bont, L. J.
    (2020)
    .
    Global molecular diversity of RSV - the "INFORM RSV" study
    .
    BMC infectious diseases
    ,
    vol
    .
    20
    ,
    p
    .
    450
    .
  5. Mendel, A., Bernatsky, S., Askanase, A., Bae, S.-C., Clarke, A. E., Costedoat-Chalumeau, N., Gladman, D. D., Gordon, C., Hanly, J., Jacobsen, S., Kalunian, K., Mak, A., Mosca, M., Pons-Estel, B. A., Ruiz-Irastorza, G., Urowitz, M. & Vinet, É.
    (2020)
    .
    Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics
    .
    Annals of the rheumatic diseases
More publications